- Home
- ABEO vs CAPR Comparison
ABEO vs CAPR Comparison
Compare ABEO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- CAPR
- Stock Information
- Founded
- ABEO 1974
- CAPR 2005
- Country
- ABEO United States
- CAPR United States
- Employees
- ABEO N/A
- CAPR N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ABEO Health Care
- CAPR Health Care
- Exchange
- ABEO Nasdaq
- CAPR Nasdaq
- Market Cap
- ABEO 289.2M
- CAPR 324.6M
- IPO Year
- ABEO 1980
- CAPR N/A
- Fundamental
- Price
- ABEO $5.26
- CAPR $7.45
- Analyst Decision
- ABEO Strong Buy
- CAPR Strong Buy
- Analyst Count
- ABEO 6
- CAPR 7
- Target Price
- ABEO $18.17
- CAPR $24.71
- AVG Volume (30 Days)
- ABEO 1.1M
- CAPR 1.4M
- Earning Date
- ABEO 11-13-2025
- CAPR 11-12-2025
- Dividend Yield
- ABEO N/A
- CAPR N/A
- EPS Growth
- ABEO N/A
- CAPR N/A
- EPS
- ABEO 0.99
- CAPR N/A
- Revenue
- ABEO $400,000.00
- CAPR $13,392,150.00
- Revenue This Year
- ABEO N/A
- CAPR N/A
- Revenue Next Year
- ABEO $324.71
- CAPR $7,894.07
- P/E Ratio
- ABEO $5.31
- CAPR N/A
- Revenue Growth
- ABEO N/A
- CAPR N/A
- 52 Week Low
- ABEO $3.93
- CAPR $5.68
- 52 Week High
- ABEO $7.54
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- ABEO 31.86
- CAPR 55.14
- Support Level
- ABEO $5.19
- CAPR $7.11
- Resistance Level
- ABEO $5.49
- CAPR $8.06
- Average True Range (ATR)
- ABEO 0.19
- CAPR 0.52
- MACD
- ABEO 0.01
- CAPR 0.20
- Stochastic Oscillator
- ABEO 12.84
- CAPR 77.81
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.